Weekly Investment Analysts’ Ratings Changes for Teva Pharmaceutical Industries (TEVA)

A number of firms have modified their ratings and price targets on shares of Teva Pharmaceutical Industries (NYSE: TEVA) recently:

• 2/18/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a “buy” rating on the stock.
• 2/9/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $45.00. They now have a “buy” rating on the stock.
• 1/31/2026 – Teva Pharmaceutical Industries was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 1/30/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at Barclays PLC from $35.00 to $38.00. They now have an “overweight” rating on the stock.
• 1/29/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at Truist Financial Corporation from $36.00 to $38.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at Scotiabank from $35.00 to $40.00. They now have a “sector outperform” rating on the stock.
• 1/21/2026 – Teva Pharmaceutical Industries had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/18/2026 – Teva Pharmaceutical Industries was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 1/10/2026 – Teva Pharmaceutical Industries was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 1/6/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at Jefferies Financial Group Inc. from $29.00 to $40.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an “overweight” rating on the stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 77,400 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. This represents a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 422,060 shares of company stock worth $12,254,965. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.